Dechra Pharmaceuticals Plc Stock Net Asset
| DPHAYDelisted Stock | USD 93.78 0.00 0.00% |
Dechra Pharmaceuticals PLC fundamentals help investors to digest information that contributes to Dechra Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Dechra Pink Sheet. The fundamental analysis module provides a way to measure Dechra Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Dechra Pharmaceuticals pink sheet.
Dechra |
Dechra Pharmaceuticals PLC Company Net Asset Analysis
Dechra Pharmaceuticals' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Dechra Pharmaceuticals Net Asset | 1.29 B |
Most of Dechra Pharmaceuticals' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Dechra Pharmaceuticals PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
CompetitionBased on the recorded statements, Dechra Pharmaceuticals PLC has a Net Asset of 1.29 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The net asset for all United States stocks is notably lower than that of the firm.
Dechra Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dechra Pharmaceuticals' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Dechra Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Dechra Pharmaceuticals by comparing valuation metrics of similar companies.Dechra Pharmaceuticals is currently under evaluation in net asset category among its peers.
Dechra Fundamentals
| Return On Equity | 0.0896 | |||
| Return On Asset | 0.0478 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.14 % | |||
| Current Valuation | 4.04 B | |||
| Shares Outstanding | 56.92 M | |||
| Shares Owned By Institutions | 0.09 % | |||
| Price To Book | 4.99 X | |||
| Price To Sales | 5.65 X | |||
| Revenue | 681.8 M | |||
| Gross Profit | 384.8 M | |||
| EBITDA | 178.9 M | |||
| Net Income | 58.2 M | |||
| Cash And Equivalents | 123.7 M | |||
| Cash Per Share | 2.29 X | |||
| Total Debt | 313.7 M | |||
| Debt To Equity | 0.49 % | |||
| Current Ratio | 2.91 X | |||
| Book Value Per Share | 12.30 X | |||
| Cash Flow From Operations | 122.9 M | |||
| Earnings Per Share | 1.29 X | |||
| Number Of Employees | 2 K | |||
| Beta | 0.68 | |||
| Market Capitalization | 4.3 B | |||
| Total Asset | 1.29 B | |||
| Z Score | 7.8 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 1.29 B | |||
| Last Dividend Paid | 0.45 |
About Dechra Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Dechra Pharmaceuticals PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dechra Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dechra Pharmaceuticals PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Other Consideration for investing in Dechra Pink Sheet
If you are still planning to invest in Dechra Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Dechra Pharmaceuticals' history and understand the potential risks before investing.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |